SAN DIEGO–(BUSINESS WIRE)–California Protons Cancer
Therapy Center today announced two major efforts representing
significant steps forward in breast cancer treatment research involving
its noninvasive, targeted proton therapy. Current California Protons
patients as of Feb. 4, 2019, are invited to enroll in the Proton
Collaborative Group (PCG) Registry of more than 13,000 patients.
Separately, the PCG BRE007-12 Partial Breast Irradiation in early stage
breast cancer clinical trial will enroll around five to eight females
per year.
The PCG Registry has been in existence since 2010 and is a prospective
tracking study that allows for the collection and analysis of patient
information to evaluate the disease process and treatment-related
outcomes, thus defining strengths and weaknesses of proton radiation
therapy. Qualified patients are invited to enroll in person at their
first physician visit during treatment.
The primary objective of the PCG BRE007-12 Partial Breast Irradiation
study is to determine freedom from ipsilateral breast recurrences in
patients receiving partial breast proton radiation therapy limited to
the region of the tumor at three years post-treatment. One of the goals
of this study is to determine whether or not limiting radiation to just
a portion of the breast is as effective as the traditional treatment of
the entire breast. A number of trials have suggested that this “partial
breast” approach is every bit as effective as treating the entire breast
and may also be less toxic. Performing such partial breast treatments
with protons can help to further reduce toxicity by taking advantage of
the protons’ ability to be precisely conformed to the target area
without giving “spillover” radiation to surrounding healthy tissue such
as the lung and heart.
PCG has partnered with 11 proton treatment centers in the U.S., and the
data has been used in close to 50 scientific manuscripts, posters and
academic presentations to date. PCG research has been presented at 20
medical conferences and has been published in a number of peer-reviewed
medical journals.
Both the Patient Registry and the Partial Breast Irradiation Trial are
Institutional Review Board (IRB)-approved. These breast cancer trials
supplement California Protons Cancer Therapy Center’s ongoing research
projects with the University of California San Diego (UCSD) and the
Radiation Therapy Oncology Group (RTOG) Foundation 3510 Phase III
randomized trial of proton versus photon therapy for patients with
nonmetastatic breast cancer receiving comprehensive nodal radiation.
About California Protons Cancer Therapy Center
California Protons’ intensity-modulated pencil beam scanning technology
is a highly precise form of cancer radiation treatment that enables
doctors to selectively target tumors with high-dose radiation while
sparing healthy tissue. California Protons’ pencil beam scanning
technology precisely delivers proton radiation treatment within 2
millimeters and with the utmost care. The treatment attacks tumors layer
by layer and minimizes harmful exposure to surrounding healthy tissue
and organs. This is important for breast cancer patients who may face
the risk of secondary cancers, lung injuries and major cardiac events
later in life due to previous radiation exposure. The reduction of
radiation-related toxicity also increases the likelihood that patients
can complete treatment with fewer interruptions or delays.
Contacts
Karen Behrman
kbehrman@marketwave.biz